Government-Owned Inventions; Availability for Licensing, 12976-12977 [2017-04501]
Download as PDF
mstockstill on DSK3G9T082PROD with NOTICES
12976
Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Integrative Nutrition and Molecular
Endocrinology.
Date: March 29, 2017.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Raul Rojas, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6185,
Bethesda, MD 20892, (301) 451–6319, rojasr@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Basic Research in Cancer Health Disparities/
Diversity.
Date: March 30–31, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Ola Mae Zack Howard,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7806, Bethesda, MD 20892, 301–451–
4467, howardz@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Mycobacterial induced immunity in HIVinfected and uninfected individuals.
Date: March 30, 2017.
Time: 8:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Silver Spring, 8727 Colesville
Road, Silver Spring, MD 20910.
Contact Person: Jingsheng Tuo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
Bethesda, MD 20892, 301–451–8754, tuoj@
nei.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–
RM16–007: Transformative Research Award
Review.
Date: March 31, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Raymond Jacobson, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5858,
MSC 7849, Bethesda, MD 20892, 301–996–
7702, jacobsonrh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–
RM16–007: Transformative Research Award
Review.
Date: March 31, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
VerDate Sep<11>2014
17:34 Mar 07, 2017
Jkt 241001
Contact Person: Raymond Jacobson, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5858,
MSC 7849, Bethesda, MD 20892, 301–996–
7702, jacobsonrh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA HD–
17–008: Autism Centers of Excellence:
Networks (R01).
Date: March 31, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Jane A. DoussardRoosevelt, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 3184, MSC 7848, Bethesda, MD 20892,
(301) 435–4445, doussarj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Project: Review of Program Project.
Date: March 31, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Jose H. Guerrier, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1137, guerriej@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: March 2, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–04484 Filed 3–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental and
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; NIDCR Loan Repayment
Program SEP.
Date: March 29–31, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Latarsha J. Carithers,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, NIDCR, 6701
Democracy Boulevard, Suite 672, Bethesda,
MD 20892, 301–594–4859,
latarsha.carithers@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: March 2, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–04482 Filed 3–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUMMARY:
E:\FR\FM\08MRN1.SGM
08MRN1
Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices
SUPPLEMENTARY INFORMATION:
Technology description follows.
AMA1–RON2 Complex-Based Vaccine
Against Malaria
Description of Technology
This technology relates to a malaria
vaccine composed of a protein complex
of Apical Membrane Antigen (AMA1)
and rhoptry neck protein 2 (RON2) with
an adjuvant. AMA1 is a crucial
component of the Plasmodium invasion
machinery and is a leading candidate
for antimalarial vaccine development.
AMA1-based vaccines have shown
ability to block red cell invasion in in
vitro assays, but protection has so far
not translated to in vivo human
infections. NIAID investigators have
demonstrated that interaction between
AMA1 and RON2 (or peptide thereof) is
essential for malaria parasites to
successfully enter human red blood
cells (RBCs). Vaccination with uncomplexed AMA1 and RON2 did not
protect against lethal malaria. However,
vaccination with a pre-formed AMA1–
RON2 complex, highlighted in this
technology, produced antibodies that
protected against lethal malaria in an in
vivo mouse model (P. yoelli) and
blocked the entry of human malaria
parasites into RBCs in vitro.
Additionally, the inhibitory antibody
response induced by the AMA1–RON2
complex was greater than AMA1 alone
or when AMA1 and RON2 proteins
were administered in a un-complexed
form.
Immunization using the AMA1–RON2
complex of this technology represents a
candidate for an effective malaria
vaccine against multiple Plasmodium
species.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Malaria vaccine
Competitive Advantages
Lower-cost malarial prevention for
developing/developed countries.
mstockstill on DSK3G9T082PROD with NOTICES
Development Stage
• Early-stage.
• In vitro data available.
• In vivo data available (animal).
Inventors: Prakash Srinivasan and
Louis Miller (NIAID).
1. Publications: Srinivasan P, et al.
Binding of Plasmodium merozoite
proteins RON2 and AMA1 triggers
commitment to invasion. Proc Natl
VerDate Sep<11>2014
17:34 Mar 07, 2017
Jkt 241001
Acad Sci U S A. 2011 Aug
9;108(32):13275–80. [PMID 21788485].
2. Srinivasan P, et al. Disrupting
malaria parasite AMA1–RON2
interaction with a small molecule
prevents erythrocyte invasion. Nat
Commun. 2013;4:2261. [PMID
23907321].
Intellectual Property: HHS Reference
No. E–066–2013/0—U.S. Provisional
Application No. 61/841,479 filed 01 Jul
2013; PCT Application No. PCT/
US2014/045065, filed July 1, 2014;
European Application No. 14742116.8,
filed July 1, 2014 (pending); U.S.
Application No. 14/902,117, filed
August December 30, 2015 (pending);
and Chinese Application No.
201480037643.1, filed December 31,
2015 (pending).
Licensing Contact: Peter Tung, 240–
669–5483; peter.tung@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability and interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize AMA1–RON2 vaccine by
providing well established human
adjuvants and clinical trial funding. For
collaboration opportunities, please
contact Peter Tung, 240–669–5483;
peter.tung@nih.gov.
Dated: February 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–04501 Filed 3–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
12977
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–16–
115: Optimization of Monoclonal Antibodies
for Eliminating the HIV Reservoir.
Date: March 28, 2017.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796, bdey@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Basic Research on HIV Persistence.
Date: March 28, 2017.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Contact Person: National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892.
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–451–2796, bdey@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Research.
Date: March 29, 2017.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: C–L Albert Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4146,
MSC 7806, Bethesda, MD 20892, 301–435–
1016, wangca@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Vaccine, Host Defense and
Inflammation.
Date: March 29, 2017.
Time: 3:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Betty Hayden, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4206,
MSC 7812, Bethesda, MD 20892, 301–435–
1223, haydenb@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
E:\FR\FM\08MRN1.SGM
08MRN1
Agencies
[Federal Register Volume 82, Number 44 (Wednesday, March 8, 2017)]
[Notices]
[Pages 12976-12977]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04501]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by communicating
with the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
[[Page 12977]]
SUPPLEMENTARY INFORMATION: Technology description follows.
AMA1-RON2 Complex-Based Vaccine Against Malaria
Description of Technology
This technology relates to a malaria vaccine composed of a protein
complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2
(RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium
invasion machinery and is a leading candidate for antimalarial vaccine
development. AMA1-based vaccines have shown ability to block red cell
invasion in in vitro assays, but protection has so far not translated
to in vivo human infections. NIAID investigators have demonstrated that
interaction between AMA1 and RON2 (or peptide thereof) is essential for
malaria parasites to successfully enter human red blood cells (RBCs).
Vaccination with un-complexed AMA1 and RON2 did not protect against
lethal malaria. However, vaccination with a pre-formed AMA1-RON2
complex, highlighted in this technology, produced antibodies that
protected against lethal malaria in an in vivo mouse model (P. yoelli)
and blocked the entry of human malaria parasites into RBCs in vitro.
Additionally, the inhibitory antibody response induced by the AMA1-RON2
complex was greater than AMA1 alone or when AMA1 and RON2 proteins were
administered in a un-complexed form.
Immunization using the AMA1-RON2 complex of this technology
represents a candidate for an effective malaria vaccine against
multiple Plasmodium species.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Malaria vaccine
Competitive Advantages
Lower-cost malarial prevention for developing/developed countries.
Development Stage
Early-stage.
In vitro data available.
In vivo data available (animal).
Inventors: Prakash Srinivasan and Louis Miller (NIAID).
1. Publications: Srinivasan P, et al. Binding of Plasmodium
merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc
Natl Acad Sci U S A. 2011 Aug 9;108(32):13275-80. [PMID 21788485].
2. Srinivasan P, et al. Disrupting malaria parasite AMA1-RON2
interaction with a small molecule prevents erythrocyte invasion. Nat
Commun. 2013;4:2261. [PMID 23907321].
Intellectual Property: HHS Reference No. E-066-2013/0--U.S.
Provisional Application No. 61/841,479 filed 01 Jul 2013; PCT
Application No. PCT/US2014/045065, filed July 1, 2014; European
Application No. 14742116.8, filed July 1, 2014 (pending); U.S.
Application No. 14/902,117, filed August December 30, 2015 (pending);
and Chinese Application No. 201480037643.1, filed December 31, 2015
(pending).
Licensing Contact: Peter Tung, 240-669-5483; peter.tung@nih.gov.
Collaborative Research Opportunity: The National Institute of Allergy
and Infectious Diseases is seeking statements of capability and
interest from parties interested in collaborative research to further
develop, evaluate or commercialize AMA1-RON2 vaccine by providing well
established human adjuvants and clinical trial funding. For
collaboration opportunities, please contact Peter Tung, 240-669-5483;
peter.tung@nih.gov.
Dated: February 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-04501 Filed 3-7-17; 8:45 am]
BILLING CODE 4140-01-P